Physician

Jeremy A Marcus, M.D.

According to 2025 Medicare claims, Jeremy Marcus, M.D. (NPI: 1528175114) practices nephrology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from The District, DC. This provider's primary affiliated billing organization is WASHINGTON NEPHROLOGY ASSOCIATES, L.L.P. (NPI: 1124193479; TIN: 521323183) and primary practice location at 20815-7227.

Marcus' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 677 traditional Medicare patients, billed 2,767 HCPCS/CPT codes, and received $293,085 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,133 prescription claims across 266 beneficiaries totaling $574,907 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 501 claims. Open Payments data shows 17 records totaling $361. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $351,411 and ending at $574,907. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	491	2,750	$277,401
2016	466	2,208	$253,618
2017	502	2,376	$274,314
2018	577	3,007	$326,764
2019	676	3,092	$338,051
2020	729	4,082	$499,442
2021	643	2,416	$346,806
2022	611	2,253	$286,994
2023	612	2,246	$289,238
2024	677	2,767	$293,085

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	128	1,487	$351,411
2016	121	1,515	$432,498
2017	128	1,542	$429,473
2018	134	1,485	$213,678
2019	150	1,397	$220,691
2020	173	1,799	$342,169
2021	168	1,550	$341,248
2022	159	1,491	$326,295
2023	175	1,493	$404,415
2024	266	2,133	$574,907

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	222	$8,664
2016	N/R	169	$5,280
2017	N/R	167	$4,726
2018	N/R	221	$7,128
2019	22	299	$8,654
2020	11	248	$8,667
2021	12	327	$10,408
2022	24	449	$20,563
2023	23	520	$20,529
2024	25	501	$19,672

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	129	142	$142
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	193	602	$100
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	100	187	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	291	483	$77
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	316	591	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	108	7,621	$133,565
Jardiance	Empagliflozin	88	7,705	$133,310
Alyq	Tadalafil	13	390	$44,545
Lokelma	Sodium Zirconium Cyclosilicate	34	1,699	$33,571
Veltassa	Patiromer Calcium Sorbitex	28	1,344	$31,476

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	25	$8,720
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	72	$2,179
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	13	155	$2,126
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	101	$1,844
J7515	Cyclosporine, oral, 25 mg	N	N/R	25	$1,764

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$361	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeremy A. Marcus, M.D.?

Tedicare shows public-source Medicare data for Jeremy A. Marcus, M.D. (NPI 1528175114), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeremy A. Marcus, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jeremy A. Marcus, M.D.?

Jeremy A. Marcus, M.D. is linked to WASHINGTON NEPHROLOGY ASSOCIATES, L.L.P. (billing NPI 1124193479) in the available physician profile data.

Does Jeremy A. Marcus, M.D. have Open Payments data?

Jeremy A. Marcus, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.